Docon Technologies, a promoter entity of Thyrocare Technologies, sold 53.32 lakh equity shares for a total consideration of ₹667.69 crore at an average price of about ₹1,252.03 per share.
Following the stake sale, Docon Technologies continues to remain a promoter of the company. The promoter shareholding has, however, declined to 60.93% from 70.98% before the transaction.
At 1 pm, shares of Thyrocare Technologies were trading 1.5% higher at ₹1,270.80 on the NSE. The stock has gained nearly 40% so far in 2025.
/images/ppid_59c68470-image-176129002629344935.webp)

/images/ppid_59c68470-image-176119003187761306.webp)
/images/ppid_59c68470-image-176120254927919157.webp)
/images/ppid_59c68470-image-176119012128131869.webp)
/images/ppid_59c68470-image-176127004241315308.webp)
/images/ppid_59c68470-image-176119762212393305.webp)
/images/ppid_59c68470-image-176119261419979386.webp)
/images/ppid_59c68470-image-17611951998119617.webp)
/images/ppid_59c68470-image-17611375345982895.webp)
/images/ppid_59c68470-image-176114502610234543.webp)
